MedPath

晋城海斯制药有限公司

Ownership
-
Established
1997-12-30
Employees
-
Market Cap
-
Website
http://www.jchszy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

139

NMPA:139

Drug Approvals

Doxapram Hydrochloride Injection

Product Name
盐酸多沙普仑注射液
Approval Number
国药准字H20093692
Approval Date
Jun 4, 2024
NMPA

Vecuronium Bromide for Injection

Product Name
注射用维库溴铵
Approval Number
国药准字H20084542
Approval Date
Dec 28, 2023
NMPA

Sodium Nitroprusside for Injection

Product Name
注射用硝普钠
Approval Number
国药准字H20084203
Approval Date
Jul 26, 2023
NMPA

Ramostron Hydrochloride for Injection

Product Name
注射用盐酸雷莫司琼
Approval Number
国药准字H20080715
Approval Date
Jul 26, 2023
NMPA

阿胶当归颗粒

Approval Number
国药准字Z20080290
Approval Date
May 30, 2023
NMPA

Olopatadine Hydrochloride Tablets

Product Name
盐酸奥洛他定片
Approval Number
国药准字H20223350
Approval Date
Feb 17, 2023
NMPA

Lansoprazole

Product Name
兰索拉唑
Approval Number
国药准字H20083182
Approval Date
Jan 5, 2023
NMPA

Vecuronium Bromide

Product Name
维库溴铵
Approval Number
国药准字H20083125
Approval Date
Jan 5, 2023
NMPA

Ambroxol Hydrochloride Granules

Product Name
盐酸氨溴索颗粒
Approval Number
国药准字H20130001
Approval Date
Jan 5, 2023
NMPA

Rabeprazole Sodium

Product Name
雷贝拉唑钠
Approval Number
国药准字H20080124
Approval Date
Jan 5, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.